Sequenom names new chief medical officer
Before joining Sequenom, Dr Bombard was the CEO of Lenetix Medical Laboratory of Mineola, New York. Prior to joining Lenetix, Dr Bombard was chief medical officer of Sharp
Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multispecific antibodies, or T-cell engagers (TCEs), for gastrointestinal (GI) cancers and other solid tumours.